Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
47 participants
OBSERVATIONAL
2002-01-31
2002-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Regulatory B Cells in Behçet's Disease
NCT04376411
MEVALONATE KINASE GENE MUTATIONS AND THEIR CLINICAL CORRELATIONS IN BEHÇET'S DISEASE
NCT01780363
Thrombophilia and Thrombosis in Behçet's Disease
NCT06451575
Cytokines in Blister Fluids of Bullous Pemphigoid (BP)
NCT03856840
The Relationship Between Serum Levels of Angiogenin, bFGF, VEGF and Ocular Involvement in Patients With Behçet's Disease
NCT01720628
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Forty-seven consecutive patients with BD (22 active, 25 inactive) meeting International Study Group Criteria , 21 age and sex matched patients with allergic rhinitis and 21 apparently healthy controls were evaluated prospectively in Rheumatology-Immunology Outpatient Clinic. Clinical activity was defined according to the criteria proposed by "Behcet's Disease Research Committee of Japan" . Activity scoring was made according to the "Behçet's Disease Research Committee of Japan" which was proposed in 1994. Organ involvements of the patients were summarized.
Patients on corticosteroids or immunosuppressives were excluded. Colchicine was stopped 10 days prior to the blood collection in inactive patients. Blood was drawn from the active patients before starting treatment. Cases with any allergy history or parasitosis were excluded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Behçet patients
eosinophil cationic protein
Serum eosinophil cationic protein levels
Healthy controls
eosinophil cationic protein
Serum eosinophil cationic protein levels
Allergic rhinitis (diseased) controls
eosinophil cationic protein
Serum eosinophil cationic protein levels
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
eosinophil cationic protein
Serum eosinophil cationic protein levels
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cukurova University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Didem Arslan Tas
Dr. Didem Arslan Tas
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hüseyin TE Ozer, Assoc. Prof.
Role: STUDY_CHAIR
Cukurova University, Faculty of Medicine, Rheumatology-Immunology Department
Eren Erken, Prof. Dr.
Role: STUDY_DIRECTOR
Cukurova University, Faculty of Medicine, Rheumatology-Immunology Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cukurova University, Faculty of Medicine, Rheumatology-Immunology Department
Adana, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TF.00.U.32.
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.